Back to search results

Web-based Program (COMPASS) for Pancreatic Cancer Patients

This study is testing a web-based program called COMPASS (Community for Physical Activity and Supportive Nutrition Strategies) for people with stage I-III pancreatic cancer who are receiving chemotherapy before surgery. The program offers personalized advice on exercise and diet, along with support through text messages, trackers, and coaching. The goal is to see if COMPASS can help patients improve their exercise and eating habits during treatment. Researchers also want to understand if the program is easy to use and if people stick with it. This is important because pancreatic cancer is rare, and there are limited resources to help patients maintain a healthy lifestyle during treatment. You can access COMPASS through a computer, tablet, or phone.

Study design
This is an interventional study with a planned enrollment of 30 participants. Participants will be randomized into one of two groups to compare different coaching approaches.
What's involved
Participants will receive access to the COMPASS web portal and tailored exercise and diet recommendations for the duration of their neoadjuvant chemotherapy. They will also attend two review sessions and may receive optional text messages three times a week.
Compensation
Not stated in the trial record.
Follow-up
The study will assess acceptability and retention for up to 12 months. Listening sessions will occur at the completion of neoadjuvant chemotherapy, which averages around 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07651358

A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy

Recruiting
NAAges 18+InterventionalSupportive care
OHSU Knight Cancer Institute
~30 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:Physical Activity and Nutritional Recommendations and Support

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Accrual (Acceptability)
Measured over Up to 12 months
+6 more outcomes measured

Conditions

Stage I Pancreatic Cancer AJCC v8
Stage II Pancreatic Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8

Explore related trials

Pancreatic Carcinoma

Where it's being run

1 sites across 1 states
Oregon1

Study leadership

  • Kerri Winters-Stone · PRINCIPAL_INVESTIGATOR · OHSU Knight Cancer Institute

Who to contact

Kerri Winters-Stone
[email protected]
503-494-0813
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older on date of enrollment
Confirmed by review of the date of birth as documented in the electronic medical record (EMR) and subsequently recorded in a case report form (CRF)
Diagnosed with stage I-III pancreatic cancer
Confirmed by EMR review. In cases where the EMR is unclear, their physician will be contacted and asked to confirm
Scheduled to receive neoadjuvant chemotherapy at Oregon Health \& Science University (OHSU)
Confirmed by EMR review. In cases where the EMR is unclear, their physician will be contacted and asked to confirm
Willing to adhere to the study protocol
Confirmed verbally with the participant and response documented in the Participant Tracking database

Exclusion

Cognitive difficulties that preclude answering the survey questions, participating in the intervention, or giving informed consent
In the event of a suspected undeclared cognitive impairment, it will be confirmed by physician clearance or professional opinion of the Principal Investigators, Dr. Kerri Winters-Stone and/or Dr. Jackilen Shannon
A medical condition, movement or neurological disorder, or medication use that contraindicates participation in light intensity exercise
Confirmed by a combination of reviewing the EMR, and self-report during the initial screening call. If in the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone or Dr. Jackilen Shannon, contraindications other than those identified by the patient or physician are present, she may consider the participant ineligible
Not fluent in English and therefore incapable of answer survey questions, reading the intervention web portal, and providing informed consent in English
Confirmed verbally with the participant and response documented in the Participant Tracking database

What this trial measures

  • Accrual (Acceptability)Up to 12 months

    Accrual will be measured by the number of eligible patients who enroll in the study divided by the total number approached for recruitment. Successful accrual will be defined as recruiting 30 pancreatic cancer patients

  • Study retention (Acceptability)Up to 12 months

    Measured by the number of participants who enroll and complete the study intervention during their neoadjuvant chemotherapy treatment. Successful retention will be if 80% (24) participants complete the study's intervention while in neoadjuvant chemotherapy.

  • Listening sessionAt completion of neoadjuvant chemotherapy (average of 6 months)

    A minimum of 2 and maximum of 4 virtual listening sessions, at least one of men and one of women will be conducted. Each group will consist of 8-10 individuals and will explore questions of ease of use, whether they felt the portal was engaging and effectively encouraged positive behaviors. Information will also be sought about how the portal may be improved.

  • Exit surveyAt completion of neoadjuvant chemotherapy (average of 6 months)

    This survey will assess which parts of the web portal and intervention participants felt were most useful. The survey includes questions about each component of the web portal and intervention, with responses ranging from "Strongly Disagree" to "Strongly Agree," as well as open-ended questions that allow participants to provide additional thoughts or comments about the web portal.

  • Study intervention adherence (Feasibility)Up to 12 months

    Adherence will be defined as the proportion of participants who achieve at least one prescribed weekly exercise goal or nutrition recommendation during ≥80% of the weeks of their neoadjuvant chemotherapy period. Values range from 0% to 100%, with higher percentages indicating greater adherence to the study intervention.

  • Web portal visit frequency (Feasibility)Up to 12 months

    Will be measured by the number of times participants logged into the web portal during the intervention period.

  • Web portal aggregate activity (Feasibility)Up to 12 months

    The number of clicks on specific web portal components, most frequently visited web pages, average time spent on the web portal and on different sections, time spent logging information or syncing Fitbit data